Rohto Pharmaceutical Co.,Ltd.
4527
주식 순위
#3839
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global... Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
주가
$19.13
시가총액
$4.32B
변동 (1일)
0.64%
변동 (1년)
16.90%
국가
JP
거래 Rohto Pharmaceutical Co.,Ltd. (4527)
카테고리
Consumer Defensive
Rohto Pharmaceutical Co.,Ltd. (4527)의 매출
Jun 2026 기준 매출 TTM: $2.31B
Rohto Pharmaceutical Co.,Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $2.31B입니다. 2024년에 회사는 $1.79B의 수익을 올렸으며 이는 2023년의 $1.80B 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Rohto Pharmaceutical Co.,Ltd.의 수익 기록 (2008 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $2.31B | 11.98% |
| 2025 | $2.06B | 15.06% |
| 2024 | $1.79B | -0.45% |
| 2023 | $1.80B | 9.63% |
| 2022 | $1.64B | 0.31% |
| 2021 | $1.63B | -6.70% |
| 2020 | $1.75B | 5.89% |
| 2019 | $1.65B | 2.34% |
| 2018 | $1.62B | 16.49% |
| 2017 | $1.39B | -6.19% |
| 2016 | $1.48B | 16.76% |
| 2015 | $1.27B | -9.28% |
| 2014 | $1.40B | 2.31% |
| 2013 | $1.37B | -5.93% |
| 2012 | $1.45B | 4.39% |
| 2011 | $1.39B | 14.55% |
| 2010 | $1.21B | 8.00% |
| 2009 | $1.12B | 3.58% |
| 2008 | $1.09B | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $87.03B | 3,674.79% |
US
|
|
| $51.67B | 2,140.87% |
FR
|
|
| $21.05B | 812.82% |
US
|
|
| $7.28B | 215.96% |
IN
|
|
| $15.05B | 552.71% |
US
|
